Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Corvus Pharmaceuticals Presents New Preclinical Data Supporting Soquelitinib's Efficacy in Systemic Sclerosis at ACR Convergence 2024 Quiver Quantitative, Inc. - Thu Nov 14, 8:00PM CST

Corvus Pharmaceuticals presents new preclinical data on soquelitinib's efficacy against immune diseases at ACR Convergence 2024.Quiver AI SummaryCorvus Pharmaceuticals has announced preclinical data supporting...

CRVS : 8.94 (+8.50%)
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis GlobeNewswire - Thu Nov 14, 9:01AM CST

CRVS : 8.94 (+8.50%)
Corvus: Q3 Earnings Snapshot AP - Tue Nov 12, 3:13PM CST

Corvus: Q3 Earnings Snapshot

CRVS : 8.94 (+8.50%)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results GlobeNewswire - Tue Nov 12, 3:01PM CST

CRVS : 8.94 (+8.50%)
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer GlobeNewswire - Sat Nov 9, 12:40PM CST

CRVS : 8.94 (+8.50%)
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 GlobeNewswire - Tue Nov 5, 3:02PM CST

CRVS : 8.94 (+8.50%)
Corvus: Q2 Earnings Snapshot AP - Tue Aug 6, 3:15PM CDT

Corvus: Q2 Earnings Snapshot

CRVS : 8.94 (+8.50%)
Corvus: Q1 Earnings Snapshot AP - Mon May 6, 3:21PM CDT

Corvus: Q1 Earnings Snapshot

CRVS : 8.94 (+8.50%)
Corvus: Q4 Earnings Snapshot AP - Tue Mar 19, 3:15PM CDT

Corvus: Q4 Earnings Snapshot

CRVS : 8.94 (+8.50%)
Corvus: Q3 Earnings Snapshot AP - Tue Nov 7, 2023

Corvus: Q3 Earnings Snapshot

CRVS : 8.94 (+8.50%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - 1 minute ago
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot